BBIO · NASDAQ · Biotechnology

BridgeBio Pharma

Develops and commercializes genetically targeted medicines through a decentralized portfolio model.

$76.60
After-hours close+0.02 (+0.03%)
At close$76.58(−2.67%)
DateEstimateReportedSurprise
Oct 2026−$0.67
Aug 2026−$0.58−$0.78−35.5%
May 2026−$0.70−$0.84−20.0%
Feb 2026−$0.71−$1.00−40.2%
Oct 2025−$0.88−$0.95−8.0%

The latest year is open to everyone — the 30 quarters behind it read with an account.

Sign in
Aug 2025
Apr 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Feb 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Nov 2021
Aug 2021
May 2021
Feb 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Nov 2019
Aug 2019
Jun 2019
Mar 2019
Sep 2018
Jun 2018
Mar 2018
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Oct 28, 2026−$0.67$267.3M
Aug 10, 2026−$0.58−$0.78−35.5%$220.9M$243.7M+10.3%
May 7, 2026−$0.70−$0.84−20.0%$178.1M$194.5M+9.2%
Feb 24, 2026−$0.71−$1.00−40.2%$146.8M$154.2M+5.0%
Oct 29, 2025−$0.88−$0.95−8.0%$148.2M$120.7M−18.5%

The latest year is open to everyone — the 30 quarters behind it read with an account.

Sign in
Aug 5, 2025
Apr 29, 2025
Feb 20, 2025
Nov 12, 2024
Aug 1, 2024
May 2, 2024
Feb 22, 2024
Nov 2, 2023
Aug 3, 2023
May 4, 2023
Feb 23, 2023
Nov 3, 2022
Aug 4, 2022
May 5, 2022
Feb 24, 2022
Nov 4, 2021
Aug 5, 2021
May 6, 2021
Feb 25, 2021
Nov 5, 2020
Aug 11, 2020
May 13, 2020
Mar 2, 2020
Nov 7, 2019
Aug 14, 2019
Jun 28, 2019
Mar 31, 2019
Sep 30, 2018
Jun 30, 2018
Mar 31, 2018